TrialThe Lancet. Respiratory medicine2025

Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.

Jordana E Hoppe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.